Michael D. Clayman - 21 Jun 2021 Form 4 Insider Report for Flexion Therapeutics Inc

Role
President and CEO, Director
Signature
/s/ Mark S. Levine, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
21 Jun 2021
Net transactions value
+$13,226
Form type
4
Filing time
28 Jun 2021, 18:04:37 UTC
Next filing
20 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FLXN Common Stock Award $13,226 +1,700 +0.49% $7.78 348,840 21 Jun 2021 Direct F1
holding FLXN Common Stock 373,769 21 Jun 2021 By the Michael D.Clayman 2006 Revocable Trust
holding FLXN Common Stock 24,600 21 Jun 2021 By the Michael D. Clayman Irrevocable Trust
holding FLXN Common Stock 388,683 21 Jun 2021 By Versant Development Fund III, LLC F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 4 is being filed voluntarily to report the acquisition of 1,700 shares by the Reporting Person on June 21, 2021, pursuant to the Issuer's Employee Stock Purchase Plan.
F2 Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.